Home treatment of haemophilia patients with inhibitors

被引:14
作者
Oyesiku, J. O. O. [1 ,2 ]
机构
[1] Churchill Hosp, Oxford Haemophilia Ctr, Oxford OX3 7LJ, England
[2] Churchill Hosp, Thrombosis Ctr, Oxford OX3 7LJ, England
关键词
haemophilia; home treatment; inhibitors; recombinant activated factor VII; ACTIVATED FACTOR-VII; QUALITY-OF-LIFE; BLEEDING EPISODES; ORTHOPEDIC STATUS; DOUBLE-BLIND; EFFICACY; RFVIIA; NOVOSEVEN; CHILDREN; THERAPY;
D O I
10.1111/j.1365-2516.2010.02418.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Bleeding episodes in patients with inhibitors can be challenging to treat. Clinical guidelines recognize the importance of early treatment, ideally within 2 h of the onset of bleeding. On-demand haemophilia care at home has been shown to reduce the time between recognition of the symptoms of bleeding and initiation of treatment. Rapid resolution of bleeding is associated with longer-term benefits for the patient. Effective haemophilia care at home depends on patients and carers taking greater responsibility for treatment; however, many find this difficult. Education can help raise awareness of haemophilia treatment at home and provide helpful information for patients/carers. The haemophilia nurse has a key role in providing this support and education. This review discusses a number of recent guidelines and educational materials for haemophilia home care identified during a literature survey. The survey shows that most materials were not validated. In addition, the survey shows limited effectiveness data on techniques for training haemophilia patients about home care. Further education resources and research in the treatment of haemophilia at home are required.
引用
收藏
页码:173 / 178
页数:6
相关论文
共 45 条
[1]  
Alliaume N, 2008, HAEMOPHILIA, V14, P124
[2]   A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study [J].
Astermark, Jan ;
Donfield, Sharyne M. ;
DiMichele, Donna M. ;
Gringeri, Alessandro ;
Gilbert, Steven A. ;
Waters, Jennifer ;
Berntorp, Erik .
BLOOD, 2007, 109 (02) :546-551
[3]   Home therapy and the effect of educational programmes in Iran; an alternative treatment option in developing countries [J].
Beheshtipour, N. ;
Cohan, N. ;
Karimi, M. .
HAEMOPHILIA, 2009, 15 (04) :966-967
[4]  
Berges A, 2008, HAEMOPHILIA, V14, P137
[5]   Inhibitors in congenital haemophilia [J].
Brettler, DB .
BAILLIERES CLINICAL HAEMATOLOGY, 1996, 9 (02) :319-329
[6]   A randomized, double-blind trial demonstrating bioequivalence of the current recombinant activated factor VII formulation and a new robust 25°C stable formulation [J].
Bysted, B. V. ;
Scharling, B. ;
Moller, T. ;
Hansen, B. L. .
HAEMOPHILIA, 2007, 13 (05) :527-532
[7]  
CHOI K, 2007, J THROMB HAEMOST, V5
[8]   European principles of haemophilia care [J].
Colvin, B. T. ;
Astermark, J. ;
Fischer, K. ;
Gringeri, A. ;
Lassila, R. ;
Schramm, W. ;
Thomas, A. ;
Ingerslev, J. .
HAEMOPHILIA, 2008, 14 (02) :361-374
[9]   Recombinant factor VIIa (Eptacog Alfa) - A review of its use in congenital hemophilia with inhibitors, acquired hemophilia, and other congenital bleeding disorders [J].
Croom, Katherine F. ;
McCormack, Paul L. .
BIODRUGS, 2008, 22 (02) :121-136
[10]   Health status and health-related quality of life of children with haemophilia from six West European countries [J].
Gringeri, A ;
von Mackensen, S ;
Auerswald, G ;
Bullinger, M ;
Garrido, RP ;
Kellermann, E ;
Khair, K ;
Lenk, H ;
Vicariot, M ;
Villar, A ;
Wermes, C .
HAEMOPHILIA, 2004, 10 :26-33